Solid Tumor
Conditions
Keywords
Liposomal Paclitaxel, Maximum tolerated dose, Dose limiting toxicity
Brief summary
The purpose of this study is to determine the maximum tolerated dose and dose limiting toxicities of liposomal paclitaxel in Chinese patients with solid tumors in advanced stages.
Detailed description
There are clinical trials show that paclitaxel is common option for the treatment of solid tumors. Liposomal paclitaxel has different pharmacokinetic features comparing with conventional paclitaxel. However,the tolerance of this new dosage form of paclitaxel (liposomal paclitaxel) has never been studied in Chinese cancer patients. This study is designed to find the maximum tolerated dose and dose limiting toxicities of liposomal paclitaxel in Chinese cancer patients.
Interventions
All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.
Sponsors
Nanjing Sike Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Age: from 18 to 70 2. Patients with solid tuomors at advanced stage must be histologically or cytologically confirmed ,and be suitable for treating with Paclitaxel Liposome solo 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS)is from 0 to 2 4. Patients who are expected to live at least 3 months 5. Laboratory tests before the study: white blood count (WBC)≥4,000/mm³,absolute neutrophil count (ANC) ≥1,500/mm³, platelet count ≥100,000/mm³, hemoglobin≥9.0 g/dL, aspartate aminotransferase AST (sGOT) and alanine aminotransferase ALT(sGPT)≤2.5 times of normal value upper limit，serum creatinine≤1.0 time of normal value upper limit，total bilirubin≤1.5 times of normal value upper limit 6. Not using chemotherapeutics (including test drug)before the study trial at least 4 weeks 7. No obvious functional disturbance diseases of internal organs 8. Complying with the study protocol 9. Sign informed consent 10. No Previous anaphylactic reaction to hormone
Exclusion criteria
1. Allergy to any medication or foods; History of hypersensitivity reactions to the conventional dosage form of paclitaxel or correlate excipients 2. Active uncontrolled central nervous system metastasis 3. Severe complications that obviously influence the compliance of patients 4. Grade ≥1 neuropathy using NCI CTCAE version 3.0 criteria 5. Taking other study medications or participating other clinical trial within 4w 6. Having radiation therapy or operation within 4w 7. Any non-remission toxicity ≥ CTC 1 in prior anticancer therapy(including radiation therapy) (except alopecie and hemoglobin) 8. Pregnant or lactant women; fertile patients not using effective contraception during study 9. No chief organ functional disturbance or diseases: * abnormal liver and renal functions * myocardial infarction * active heart disease * neuropathy or mental diseases including dementia or epilepsy * blind、deaf、dumb or extremity disability * known infection * active diffuse intravascular coagulation 10. Others whom researchers regard not eligible for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| maximum tolerated dose | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| dose limiting toxicity | 6 months |
Countries
China
Outcome results
None listed